Apixaban

證據等級: L5

預測適應症: 10 個

Apixaban: From Atrial Fibrillation & Venous Thromboembolism to Pulmonary Hypertension

One-Sentence Summary

Apixaban (Eliquis, DrugBank: DB06605) is a direct oral Factor Xa inhibitor approved for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of deep vein thrombosis and pulmonary embolism. This multi-indication evidence pack (10 TxGNN predictions) identifies Pulmonary Hypertension — specifically systemic sclerosis-related PAH (SSc-PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) — as the most clinically actionable new indication, supported by a multicentre placebo-controlled RCT protocol (SPHInX study) directly testing Apixaban in SSc-PAH and 19 publications. Most other high-ranking predictions (three migraine subtypes, leprosy, Prinzmetal angina, two rare skeletal syndromes) lack mechanistic rationale or carry negative evidence and are classified as Hold.

Quick Overview

Item	Content
Original Indication	Prevention of stroke/systemic embolism in non-valvular AF; treatment and prevention of DVT and PE; post-surgical VTE prophylaxis (hip/knee replacement)
Most Actionable Predicted Indication	Pulmonary Hypertension (SSc-PAH / CTEPH)
TxGNN Prediction Score	98.13%
Evidence Level	L3
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails (Pulmonary Hypertension)

All Predictions at a Glance

Rank	Disease	TxGNN Score	Evidence Level	Decision
1	Migraine disorder	99.02%	L4	Research Question
2	Migraine with/without aura, susceptibility	98.92%	L5	Hold
3	Leprosy	98.90%	L5	Hold
4	Rheumatoid arthritis	98.89%	L4	Research Question
5	Migraine with brainstem aura	98.83%	L4	Hold
6	Prinzmetal angina	98.39%	L5	Hold
7	Brachydactyly-syndactyly syndrome	98.18%	L5	Hold
8	Pulmonary hypertension	98.13%	L3	Proceed with Guardrails
9	Colobomatous microphthalmia-rhizomelic dysplasia syndrome	97.99%	L5	Hold
10	Kyphoscoliotic heart disease	97.87%	L5	Hold

Why is This Prediction Reasonable?

Apixaban selectively and reversibly inhibits both free and clot-bound Factor Xa (FXa), thereby reducing thrombin generation independent of antithrombin III. This mechanism is directly relevant to pulmonary hypertension through two distinct disease pathways. Detailed MOA data was not available in the evidence pack, but Apixaban’s mechanism is well established in the published literature.

For Chronic Thromboembolic Pulmonary Hypertension (CTEPH), the connection is straightforward: Apixaban is already approved for treating acute pulmonary embolism, the precursor condition to CTEPH. Organised pulmonary thrombi in CTEPH obstruct the pulmonary vasculature, and lifelong anticoagulation is a treatment cornerstone. Emerging observational data (PMID 29791520; PMID 39468095) confirm that FXa inhibitors including Apixaban are being used clinically in CTEPH patients with measurable anti-FXa activity at both peak and trough.

For Systemic Sclerosis-related PAH (SSc-PAH), the mechanism is more novel. FXa activates protease-activated receptors PAR-1 and PAR-2 on pulmonary endothelial cells and fibroblasts, triggering TGF-β-mediated vascular remodelling and fibrosis. In situ thrombosis in peripheral pulmonary vessels — driven by endothelial dysfunction and imbalance of anticoagulant/prothrombotic mediators — is a recognised contributor to SSc-PAH pathogenesis. By inhibiting FXa, Apixaban may simultaneously reduce micro-thrombosis and attenuate profibrotic PAR signalling. This dual rationale directly motivated the SPHInX study (PMID 27932335), a multicentre randomised placebo-controlled trial specifically designed to test Apixaban in SSc-PAH.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03610217	N/A	Unknown	400	SPHInX study: Pragmatic multicentre RCT in systemic sclerosis patients testing Apixaban vs placebo. SSc-PAH develops in 12–15% of SSc patients and accounts for 30–40% of SSc deaths. Protocol published (PMID 27932335); trial status requires direct confirmation with investigators.
NCT06370273	Phase 3	Recruiting	10,044	TiLLI study: Thromboprophylaxis (including Apixaban tablets) vs standard injection care vs no medication in lower limb immobilisation. PE prevention data relevant to CTEPH risk reduction. Completion: August 2028.
NCT02942407	Phase 4	Completed	154	RENAL-AF: Apixaban vs warfarin in hemodialysis AF patients. Demonstrates Apixaban safety/efficacy in high-risk comorbid populations with cardiovascular and renal complications.
NCT05838664	N/A	Completed	2,140,403	SIFNOS: Large French retrospective cohort of AF patients on/off oral anticoagulants (2016–2020). Stroke, major bleeding, and mortality outcomes in real-world setting.
NCT04234698	N/A	Completed	2,076	Colombian observational cohort of NVAF patients initiating OACs; treatment patterns and time to clinical events. Provides real-world comparative context.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27932335	2016	RCT Protocol	BMJ Open	SPHInX study protocol: multicentre placebo-controlled RCT of Apixaban in SSc-PAH. Rationale: endothelial dysfunction, in situ thrombosis, FXa–PAR–TGF-β signalling drive SSc-PAH. Direct evidence for Apixaban repurposing hypothesis.
38910594	2024	Review	J Scleroderma Relat Disord	Anticoagulation reconsidered in SSc: endothelial damage activates coagulation cascade; reviews evidence for DOAC use and argues for anticoagulant role in SSc vascular management.
39468095	2024	Clinical Study	Scientific Reports	Anti-FXa activity monitoring in 50 CTEPH patients on FXa inhibitors (rivaroxaban, apixaban, edoxaban): evaluates therapeutic range at peak and trough; first real-world DOAC pharmacokinetics data specific to CTEPH.
36335915	2023	RCT	Circulation	AXADIA-AFNET 8: Apixaban vs phenprocoumon (VKA) in AF patients on chronic hemodialysis. Supports Apixaban use in complex cardiovascular/renal comorbidity profile.
40023651	2025	RCT	The Lancet	Extended VTE treatment: reduced-dose vs full-dose DOAC in high-recurrence-risk patients. Efficacy and safety of long-term Apixaban; relevant to CTEPH maintenance anticoagulation.
29791520	2018	Clinical Review	Clinics (São Paulo)	DOAC use in CTEPH: reviews emerging evidence for FXa inhibitors as viable alternative to VKA in CTEPH; limited data but mechanistically coherent rationale.
24875390	2014	Clinical Study	Thrombosis Research	Acute DVT/PE treatment with NOACs in special populations; highlights CTEPH as major long-term PE complication; Apixaban efficacy in reducing pulmonary thrombus burden.
38033089	2024	Guideline	Circulation	2023 ACC/AHA/ACCP/HRS AF guideline: Apixaban recommended as first-line OAC for AF stroke prevention. Establishes safety and dosing benchmark for cardiovascular use.
35648447	2022	Case Report	Texas Heart Institute Journal	Trousseau syndrome with CTEPH and Lynch syndrome: staged surgical/medical management including Apixaban in complex thrombotic pulmonary hypertension.

Notable Secondary Finding: Rheumatoid Arthritis (Rank 4 — Research Question)

A 2020 preclinical study provides direct mechanistic evidence worth pursuing. Activated FXa signals through PAR-2 on synovial fibroblasts (FLS), activating JAK2/STAT3 and MAPK phosphorylation cascades that upregulate IL-6 and TNF-α. In a complete Freund’s adjuvant rat model, Apixaban significantly reduced joint inflammation, paw oedema, and pro-inflammatory cytokine levels (PMID 32141012). No clinical trials have tested Apixaban specifically for RA, and there are no conflicting results in this direction (unlike the migraine predictions). This constitutes a valid Research Question warranting further mechanistic validation.

PMID	Year	Type	Journal	Key Findings
32141012	2020	Preclinical Study	Inflammopharmacology	Apixaban inhibits FXa-mediated JAK2/STAT3 and MAPK phosphorylation in FLS cells; significant anti-arthritic effect in rat CFA model; reduced IL-6, TNF-α, paw swelling. Direct mechanistic study.

Predictions Recommended for Hold — Summary

Disease	Core Reason
Migraine with/without aura, susceptibility (rank 2)	19 of 20 literature items are epilepsy genetics studies unrelated to Apixaban; only Apixaban-specific paper (PMID 37582651) is a negative case report (migraine worsened). “Susceptibility” is a genetic trait, not a treatment endpoint.
Leprosy (rank 3)	Sole evidence (PMID 38149553) is a VTE complication case in a leprosy patient — Apixaban treated the PE, not the infection. No anti-mycobacterial FXa inhibitor mechanism exists.
Migraine with brainstem aura (rank 5)	All 3 case reports are negative/neutral: Warfarin resolves migraine but Apixaban does not (PMID 28960288); Apixaban worsens migraine (PMID 37582651). Evidence direction is explicitly negative.
Prinzmetal angina (rank 6)	Pathology is coronary vasospasm (smooth muscle dysfunction), not thrombosis. FXa inhibition has no pharmacological mechanism for vasospasm. Zero evidence.
Brachydactyly-syndactyly syndrome (rank 7)	Congenital skeletal malformation from BMP/GDF5 pathway mutations; irreversible structural defect; no FXa inhibitor mechanism. KG false positive.
Colobomatous microphthalmia-rhizomelic dysplasia (rank 9)	Extremely rare congenital syndrome (PAX2/CHD7 mutations); structural embryonic defect with no FXa connection. KG false positive.
Kyphoscoliotic heart disease (rank 10)	Secondary PH from restrictive lung disease; theoretical VTE risk but no clinical evidence exists for this specific entity. May follow PH anticoagulation logic — evaluate within PH framework instead.

For migraine disorder (rank 1): The PFO–cortical spreading depression hypothesis offers indirect biological plausibility (microemboli → CSD → migraine aura). However, the sole trial (NCT00562289) tests VKA anticoagulation, not Apixaban, and two case reports directly show Apixaban is inferior to Warfarin in this setting. Classified as Research Question — requires PFO-stratified hypothesis-driven investigation before clinical translation.

India Market Information

Apixaban has no registered products in India per current system data (0 CDSCO licences). No approved indications are available domestically.

Note: This may reflect incomplete registry data. The drug is globally approved and marketed (Eliquis, Bristol-Myers Squibb/Pfizer) in over 100 countries. Current CDSCO approval status should be independently verified at the official CDSCO portal before any regulatory strategy decisions.

Safety Considerations

Full CDSCO package insert data is not available in this evidence pack. Based on global prescribing information and published evidence:

Bleeding Risk: Apixaban substantially increases risk of major and fatal bleeding. Not recommended with active clinically significant haemorrhage, severe hepatic impairment, or for patients with prosthetic heart valves.
Drug Interactions: Strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir) markedly increase Apixaban exposure. Strong dual inducers (e.g., rifampicin, carbamazepine, St. John’s wort) reduce efficacy substantially.
PH-Specific Caution: In SSc-PAH patients receiving concurrent vasodilator therapy (e.g., endothelin receptor antagonists, PDE-5 inhibitors), monitor for additive hypotension and increased bleeding risk, particularly in the context of thrombocytopenia which is common in SSc.
Renal Impairment: Dose adjustment required; not recommended in severe renal impairment (CrCl < 15 mL/min).

Conclusion and Next Steps

Decision: Proceed with Guardrails — Pulmonary Hypertension

Rationale: The SPHInX study (PMID 27932335) is a purpose-designed multicentre placebo-controlled RCT testing Apixaban specifically in SSc-PAH, providing the highest-quality evidence framework for this repurposing direction. Complementary observational data supports FXa inhibitor use in CTEPH (PMID 39468095), and the FXa–PAR–TGF-β mechanistic pathway in pulmonary vascular remodelling is biologically coherent and experimentally supported.

To proceed, the following is needed:

Confirm SPHInX study (NCT03610217) outcome data — trial status is listed as “Unknown”; contact lead investigator (Calderone et al., Australia) or search publication database for results
Retrieve and review CDSCO package insert and obtain full Indian regulatory approval status for Apixaban
Conduct targeted literature search specifically for CTEPH + Apixaban outcomes (starting from PMID 39468095 and references therein)
Define patient population scope: CTEPH (strongest rationale, closest to on-label use) vs SSc-PAH (greater mechanistic novelty, clearer off-label territory)
Design haemodynamic and haematological safety monitoring plan for PH population in any local investigator-initiated trial

Decision: Research Question — Rheumatoid Arthritis

Rationale: The FXa–JAK2/STAT3–MAPK anti-arthritic mechanism is directly demonstrated in preclinical models (PMID 32141012), with no conflicting clinical signals. This warrants prospective translational research.